Germany has approved a large phase 2b study on psilocybin for treatment-resistant depression. Dr. Gerhard Gründer, of the Central Institute of Mental Health Mannheim, will lead the study alongside the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results